NXC736

DRUG2 trials

Sponsors

NEXTGEN Bioscience

Conditions

Alopecia AreataHealthy

Phase 1

A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants

CompletedNCT05079425

NEXTGEN BioscienceHealthy

Start: 2021-09-01End: 2022-11-01Updated: 2023-02-08

Phase 2

Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

RecruitingNCT06104839

NEXTGEN BioscienceAlopecia Areata

Start: 2024-09-01End: 2027-01-31Target: 73Updated: 2026-04-13